tbuckley/cabot-search huggingface dataset:
FRI0314 Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS Action) Clinical Database and Repository Analysis: The Impact of Systemic Lupus Erythematosus on The Clinical Phenotype of Antiphospholipid Antibody-Positive Patients
Authors: S. Zuily, D. Andrade, D. Erkan, M. Tektonidou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients with or without autoimmune disorders over 10 years. The main autoimmune disease associated with aPL is Systemic Lupus Erythematosus (SLE); limited data exist on the impact of SLE on the clinical phenotype of persistently aPL-positive patients. <h3>Objectives</h3> Our objective was to compare the prevalence of clinical and laboratory characteristics of aPL-positive patients with or without SLE. <h3>Methods</h3> A secure web-based data capture system is used to store patient demographics, pertinent aPL history, and aPL profile. The inclusion criteria include aPL positivity according to the Updated Sapporo Classification Criteria. Only patients fulfilling the ACR SLE Classification Criteria and those with no other autoimmune diseases were included in this cross sectional analysis to study the impact of SLE on aPL-positive patients. Baseline clinical characteristics were compared using χ<sup>2</sup> or t-tests accordingly. <h3>Results</h3> As of June 2015, 573 aPL-positive patients recruited from 24 centers; 130 (22.7%) were excluded due to other or overlapping autoimmune diseases, SLE-like disease (fulfilling 3/11 ACR SLE Classification Criteria), or missing data. The mean ages (± SD) of individuals with persistently positive aPL but without other autoimmune diseases (“aPL only”) (female: 218, 73%), and of those with SLE (“aPL with SLE”) (female: 110, 77%) were 44±13 and 49±77, respectively. The majority of patients were Caucasians in both groups (62% and 65%, respectively), followed by Latin Americans (19.3% and 10.5%). Table shows the distribution of the clinical and laboratory characteristics (historically and/or at registry entry). The frequency of criteria and non-criteria APS manifestations was not different between two groups except persistent thrombocytopenia and autoimmune hemolytic anemia, which were more common in the “aPL with SLE” group (14% vs 28% and 2% vs 12%, respectively; both p≤0.001). Nephrotic syndrome, chronic or end-stage renal disease, and hypocomplementemia were also more common in the “apL with SLE” group. <h3>Conclusions</h3> Concomitant SLE diagnosis in persistently aPL-positive patients is associated with an increased risk of thrombocytopenia, hemolytic anemia, nephrotic syndrome, chronic or end-stage renal disease, and hypocomplementemia; however the risk of other non-criteria manifestations, thrombosis, and pregnancy morbidity remains the same. <h3>Acknowledgement</h3> APS ACTION Members. <h3>Disclosure of Interest</h3> None declared
Mid-Treatment 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Does Not Impact the Outcome in Patients with Aggressive Non Hodgkin Lymphoma (NHL)
Authors: Patrizia Pregno, Annalisa Chiappella, Marilena Bellò, Giulia Benevolo, Carola Boccomini, Barbara Botto, Chiara Frairia, Roberto Freilone, Lorella Orsucci, Roberto Passera, Giovanni Bisi, Umberto Vitolo
Journal: Blood (2008)
Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype
Authors: Aziz Nazha, David J. Seastone, Priyanka A Pophali, Tomas Radivoyevitch, Hetty E. Carraway, Anjali S. Advani, Matt E. Kalaycio, Gina Rupp, Kristin Colaluca, Bartlomiej P Przychodzen, Hideki Makishima, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2014)
Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma
Authors: Gonzalo Gutierrez-Garcia, Teresa Cardesa, Luis Colomo, Fina Climent, Santiago Mercadal, Jose Luis Mate, Juan Manuel Sancho, Lourdes Escoda, Sergi Serrano, Antonio Martinez, Pedro Jares, Adriana Garcia-Herrera, Alejandra Martinez-Trillos, Pau Abrisqueta, Magdalena Pinyol, Alexandra Valera, Leonor Arenillas, Eva Gine, Neus Villamor, Francesc Bosch, Elias Campo, Armando Lopez-Guillermo
Journal: Blood (2010)
The Methylation Status of p21 Is Not Relevant in Adult Acute Lymphoblastic Leukemia Patients.
Authors: Chiara Gregorj, Fabiana De Cave, Maria R. Ricciardi, Maria C. Scerpa, Cristina M. Precupanu, Jacopo Gervasoni, Maria L. Iannitto, Paola Fazi, Stefania Gubbiotti, Giorgina Specchia, Alessandra Cupri, Felicetto Ferrara, Francesca Mondello, Ciro Rinaldi, Giuseppe Fioritoni, Nicola Cascavilla, Eustachio Miraglia, Luciana Annino, Ernesta Audisio, Patrizio Mazza, Antonio Peta, Alfonso M. D’Arco, Catia Bigatti, Alessandra Tedeschi, Robin Foà, Agostino Tafuri, Maria Teresa Petrucci
Journal: Blood (2005)
Addition of Pegylated Megakaryocyte Growth Development Factor (pegMGDF) to G-CSF Improves the Mobilization of Primitive Hemopoietic Cells.
Authors: Stephen R. Larsen, Keefe Chng, Margaret Armstrong, Fiona Battah, Marcus Hayward, Louie Leung, Sally Thomson, Annemarie Hennessy, John Gibson, Douglas E. Joshua, John E.J. Rasko
Journal: Blood (2005)
Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study
Authors: Antonello Pinto, Vincenzo Pavone, Francesco Angrilli, Mariangela Saggese, Stefania Crisci, Caterina Patti, Pier Luigi Zinzani, Alfonso Maria D'Arco, Elena Cavalieri, Attilio Guarini, Michele Spina, Daniela Carlino, Simona Falorio, Emanuela Morelli, Manuela Arcamone, Ferdinando Frigeri, Annarosaria De Chiara, Rosaria De Filippi, Gaetano Corazzelli
Journal: Blood (2015)
FRI0566 Attributes of The Subcutaneous Biologic Therapy Preferred by Patients with Rheumatic Disease and Satisfaction with The Treatment. RHEU LIFE Survey:
Authors: C.M. González, L. Carmona, F.J. de Toro, M.J. Arteaga, S. Fernández, L. Cea-Calvo, E. Batlle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Preferences of patients and satisfaction with the medication are important to improve adherence and outcomes. <h3>Objectives</h3> In patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA) and psoriatic arthritis (PsA), we explored the attributes of drugs preferred by them, and the degree of satisfaction with the current medication. <h3>Methods</h3> RHEU-LIFE was a survey to patients &gt;18 years-old with RA axial SpA or PsA treated with subcutaneous (SC) biological drugs, from 50 outpatient rheumatology hospital clinics. Patients responded anonymously to the survey. They ranked 5 treatment attributes from 1 (the most important) to 5 (the least important), and expressed their satisfaction with each one from "very satisfied" to "very dissatisfied". <h3>Results</h3> The survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years, 42.4% men and 57.6% women; underlying disease RA: 304 (54.2%), axial SpA: 141 (25.1%), PsA: 116 (20.7%), not identified: 31. The biological drug was first (60.4%), second (26.8%) and third or more (13.5%). The attributes mentioned most frequently as "the most important" were normalization of quality of life (QoL) and symptoms control (43.6% and 32.5%, table). The importance was similar in patients with different diseases or treated with first, second or third biologic. The percentage "satisfied" or "very satisfied" was high for every attribute (80% or higher, table) and similar between patients with different conditions. The percentage "satisfied" or "very satisfied" with symptoms control and normalization of QoL was greater in those receiving the first biologic (87.8% and 85.7%) and lower with the third or more (78.4% and 72.0%, both p&lt;0.05). No differences were found for the rest of the attributes. <h3>Conclusions</h3> Patients with rheumatic diseases treated with SC biological drugs give more importance to normalization of the quality of life and symptom control than to tolerability, speed of action and the comfort or easeness of use, and express a high degree of satisfaction with their current treatment, especially those receiving therapy with a first biologic. <h3>Acknowledgement</h3> Financed by Merck Sharp &amp; Dohme of Spain and endorsed by the patients9 association ConArtritis (Arthritis National Coordinator). <h3>Disclosure of Interest</h3> None declared
SP0057 Data Visualisation: Tables and Graphs for Publication and Presentation
Authors: M. Boers
Journal: Annals of the Rheumatic Diseases (2016)

This workshop (repeated on Friday, 15:30, Capital Suite 06) is an introduction to the principles of good graph and table design as pioneered by Cleveland<sup>1</sup> and Tufte<sup>2</sup> and updated by Few<sup>3</sup> so that the participant can better answer the following questions: Which of the messages in my research results requires a graph or table? Recognizing how graphs improve on simple statistics and convey much more information. Knowing when a table is better, or keeping the data in the body text. How can I best convey the message? Striving for clear vision by choice of graph, scaling, discrimination of data series, minimizing non-data ink, avoiding chart junk.Striving for clear understanding through a balance between data and explanation. Using order, subheadings, formatting and rules to guide your reader through your table data. Is my graph/table truthful? Creating a direct proportion between graph and data quantities, avoiding forms prone to misinterpretation, labels to prevent ambiguity; keeping data in context, avoiding more dimensions in the graph than in the data. <h3>References</h3> Cleveland WS. The elements of graphing data: Hobart Press, Summit, NJ, USA; 1994. Tufte E. The visual display of quantitative information. 2nd ed: Graphics Press, Cheshire, CT, USA; 2001. Few S. Show me the numbers. Designing tables and graphs to enlighten. Analytics Press, Oakland, CA, USA; 2004. <h3>Disclosure of Interest</h3> None declared
FRI0519 Ultrasound Definition of Cartilage Change in Patients with Rheumatoid Arthritis: A Reliability Study by The Omeract Ultrasonography
Authors: P. Mandl, E. Filippucci, F. Alasti, A. Bachta, M. Backhaus, D. Bong, G.A. Bruyn, P. Collado, N. Damjanov, C. Dejaco, A. Delle-Sedie, C. Duftner, M. Gutierrez, H.B. Hammer, C. Hernandez Diaz, A. Iagnocco, K. Ikeda, D. Kane, H. Keen, S. Kelly, E. Kővári, E. De Miguel, I. Möller, U. Moller-Dohn, E. Naredo, J.C. Nieto, C. Pineda, A. Rodriguez, W.A. Schmidt, M. Szkudlarek, L. Terslev, R. Thiele, R. Wakefield, D. Windschall, M.-A. D'Agostino, P.V. Balint
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To produce ultrasound (US) consensus-based definitions of cartilage change in rheumatoid arthritis (RA) and assess its intraobserver and interobserver reliability in a web-based exercise. <h3>Methods</h3> We conducted a Delphi study on US defined cartilage change and a proposed semiquantitative (SQ) US scoring system for cartilage change in RA. A written Delphi questionnaire was developed based on a systematic literature review and expert international consensus and was distributed via consecutive written questionnaires by email to a group 35 rheumatologists from 17 countries with experience in musculoskeletal US. Taskforce members performed US B mode examination of the metacarpal cartilage in metacarpophalangeal joints 2–5 in RA patients and the images were collected in an electronic database. A reference image atlas of cartilage changes was developed for scoring 123 anonymized images including 25 duplicate images. These were sent to the participants who independently scored the images. Intraobserver reliability was assessed by Cohen9s kappa and interobserver reliability by Fleiss9 kappa. <h3>Results</h3> Group agreement (76–100%) was reached for 6 statements concerning: i) MSUS definition and assessment of normal hyaline cartilage, ii) elementary cartilage lesions in MSUS and iii) grading of elementary cartilage lesions in patients with RA in a two-round Delphi consensus process. A three-grade SQ (0–2) scoring system (grade 0, normal cartilage; grade 1, minimal change: blurring of outer and/or subchondral margin, focal thinning or incomplete loss of homogeneity of echostructure; grade 2, severe: diffuse thinning or complete loss of homogeneity of echostructure) was agreed for scoring cartilage damage in RA. Both intra- and inter-observer reliability were good (κ value of 0.87 and 0.64 respectively). <h3>Conclusions</h3> This study demonstrates that US is a reliable tool for evaluating cartilage in RA and strongly supports the use of a new reliable semiquantitative MSUS scoring system for cartilage change. <h3>Disclosure of Interest</h3> None declared
Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury
Authors: Irina A. Leaf, Shunsaku Nakagawa, Bryce G. Johnson, Jin Joo Cha, Kristen Mittelsteadt, Kevin M. Guckian, Ivan G. Gomez, William A. Altemeier, Jeremy S. Duffield
Journal: Journal of Clinical Investigation (2016)

Fibrotic disease is associated with matrix deposition that results in the loss of organ function. Pericytes, the precursors of myofibroblasts, are a source of pathological matrix collagens and may be promising targets for treating fibrogenesis. Here, we have shown that pericytes activate a TLR2/4- and MyD88-dependent proinflammatory program in response to tissue injury. Similarly to classic immune cells, pericytes activate the NLRP3 inflammasome, leading to IL-1β and IL-18 secretion. Released IL-1β signals through pericyte MyD88 to amplify this response. Unexpectedly, we found that MyD88 and its downstream effector kinase IRAK4 intrinsically control pericyte migration and conversion to myofibroblasts. Specific ablation of MyD88 in pericytes or pharmacological inhibition of MyD88 signaling by an IRAK4 inhibitor in vivo protected against kidney injury by profoundly attenuating tissue injury, activation, and differentiation of myofibroblasts. Our data show that in pericytes, MyD88 and IRAK4 are key regulators of 2 major injury responses: inflammatory and fibrogenic. Moreover, these findings suggest that disruption of this MyD88-dependent pathway in pericytes might be a potential therapeutic approach to inhibit fibrogenesis and promote regeneration.
B7.2 and B7-H2 Molecules Stimulate Proliferation of Myeloma Cells and Inhibit Anti-Myeloma Immune Responses.
Authors: Taishi Yamashita, Hideto Tamura, Chikako Sato, Asaka Kondo, Takashi Tsuji, Kazuo Dan, Kiyoyuki Ogata
Journal: Blood (2007)
A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia
Authors: Mao Zhang, Pariya Sukhumalchandra, Atim A. Enyenihi, Lisa S St. John, Sally A. Hunsucker, Kathryn Ruisaard, Zein Al Atrache, Patricia A Ropp, Tania Rodriguez-Cruz, Elizabeth Mittendorf, Gregory Lizee, Karen Clise-Dwyer, Sijie Lu, Gary L. Glish, Jeffrey J. Molldrem, Paul M Armistead, Gheath Alatrash
Journal: Blood (2011)
FRI0482 Anti-TNFα Therapy and Switching in Severe Uveitis of Vogt-Koyanagi-Harada Syndrome. Report of Two Cases and Literature Review: Table 1
Authors: B.J. Flores, C. Fernández, J. Blanco, N. Palmou Fontana, R. Blanco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Vogt-Koyanagi-Harada disease is a multisystem autoimmune disorder mediated by T-cells directed against antigens of tissues that contain melanin. Clinically it9s characterized by diffuse bilateral granulomatous panuveitis. Although conventional immunosuppresive therapy such as cyclosporine (CsA), azathioprine (AZA) or methotrexate (MTX) the disease can remain active and complicated by blindness. <h3>Objectives</h3> Our aim was to review the cases of VKH syndrome uveitis in a reference unit for the past five years especially those patients with anti-TNFα therapy. <h3>Methods</h3> We reviewed all the cases of posterior uveitis or panuveitis in a reference unit between January 2010 to December 2015. VKH syndrome was diagnosed by international standard criteria <sup>(1).</sup> The treatment was reviewed particularly those with anti-TNFa therapy refractory to conventional immunosuppresives. In addition we reviewed the literature of anti-TNF α therapy in a VKH uveitis syndrome <h3>Results</h3> 104 were assessed. 5 cases (4 wome /1 man) met criteria VKH syndrome, mean age was 45 years. In all cases the initial treatment was high doses of corticosteroids and conventional immunosuppressive therapy CyA (4 cases), AZA (2 Cases) CsA + AZA (2 cases). In two patients with failure to AZA + CsA, infliximab (IFX) was prescribed Weeks 0, 2 and 6 and each 8 weeks. In both cases (intorelancy and ineffectiveness to infliximab), "switch" to adalimumab 40 mg/sc biweekly achieving an adequate clinical response and remission of uveitis. In addition to the two cases in our series in the literature review we found 9 articles related to anti-TNF α therapy in VKH syndrome (Table). We found 9 series with 25 patients (14 with ADA/11 IFX). In most of them remission of intraocular inflammation was observed, 13 patients with ADA (92.8%)/10 IFX (90.9%). There are no published cases of "Switching" between anti-TNF agents in VKH. <h3>Conclusions</h3> In VKH syndrome uveitis refractory to conventional immunosuppressive, anti-TNF therapy may be a treatment option. In cases of inadequate response to the first anti-TNFa "switching" to another anti-TNFa is an option, however, these preliminary data should be tested in randomized prospective studies with larger numbers of patients. <h3>References</h3> Autoimmunity reviews. 2013; 12: 1033–1038. Rest of references in the table (2–10), <h3>Disclosure of Interest</h3> None declared
a Pediatric Primary Renal Lymphoma Case Presenting with Acute Renal Failure Findings
Authors: Fahrinnisa Ferhan Akici, Deniz Tugcu, Gonul Aydogan, Zafer Salcioglu, Hulya Sayilan Sen, Arzu Akcay, Aysel Kiyak, Oner Dogan, Yurdanur - Kilinc
Journal: Blood (2014)
Methylation of HAI-2/SPINT2 in Bone Marrow Mesenchymal Stromal Cells of MDS and AML Patients Affects Hematopoietic Stem Cell Survival and Adhesion
Authors: Fernanda Marconi Roversi, Nathalia Moreno Cury, Matheus Rodrigues Lopes, Fernando Vieira Pericole, Marisa Claudia Alvarez Prax, Karla Priscila Ferro, Patricia Favaro, José Andres Yunes, Sara T. Olalla Saad
Journal: Blood (2015)
CD44v6 Is Required For In Vivo Tumorigenesis Of Human AML and MM Cells: Role Of Microenvironmental Signals and Therapeutic Implications
Authors: Benedetta Nicolis di Robilant, Monica Casucci, Laura Falcone, Barbara Camisa, Bernhard Gentner, Luigi Naldini, Claudio Bordignon, Fabio Ciceri, Chiara Bonini, Attilio Bondanza
Journal: Blood (2013)
Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.
Authors: J. Porter, C. Borgna-Pignatti, M. Baccarani, A. Saviano, S. Abish, R. Malizia, H. Nick, H. Opitz, B. Rabault, I. Gathmann, P. Marks
Journal: Blood (2005)
PTU-087 Developing Models of Engagement in a New Migrant Population: Results from a Large Scale Hepatitis B &amp; C Testing Study in the UK Nepali Community
Authors: S Mathew, M Petrova, J Hendy, J Van Vlymen, S Jones, S de Lusignan, J Zamani, A Pilcher, R Tiwari, M Nicholls, A Ala, A Ala
Journal: Gut (2016)

<h3>Introduction</h3> The UK Nepali community has grown by over 900% since 2004, when settlement rights were introduced for ex-Gurkha servicemen and their dependants. Nepal sits between India and China; two countries with higher rates of hepatitis B &amp; C, but rates in the UK Nepali population is unknown <h3>Methods</h3> The Nepali community has multiple castes and religious beliefs. Little is known about disease and healthcare perception, and focus group sessions were held before testing. National ethics approval was obtained, and testing sessions were held in community venues centrally located to known population clusters in Surrey, UK. Study advertising was limited to existing Nepali language media and word of mouth, following concerns raised by the activity of far right groups. Fingerprick testing was used, with community leaders helping to facilitate testing. Questionnaires were used for possible risk associations including: blood transfusions, surgery, and place of origin. <h3>Results</h3> 1005 Nepali individuals (age &gt; 18 yrs, Male = 45%) were tested over 17 sessions from Mar 2013 - Jan 2015. A total of 973 individuals were included in final analysis (mean age 63 yrs, range 19–86). Median length of stay in the UK was 36 months, with 18 individuals (1.8%) present in the UK for more than 10 years HBsAg was detected in 3 (0.31%) and HCVAb in 4 (0.41%) separate individuals; showing low rates of infection. HBsAg patients had absent or low level HBV DNA (&lt;300iu/ml), and all HCV patients were RNA negative, with no evidence of cirrhosis in attending patients on follow-up (5/7). Hepatitis B core Ab (HBcAb) was detected in 93 individuals (9.6%), mean age 67 yrs (22–84 yrs) Regression analysis showed no statistical associations with HBsAg / HCVAb presence; but HBcAb was significantly associated with male gender and fewer years spent at school (p = 0.002 and p = 0.02 respectively) <h3>Conclusion</h3> Rates of active CVH were very low in the Nepali community, but with higher rates of previous HBV exposure, which may have implications for ongoing testing programmes. Given the absence of a common religious or cultural forum to target this new community, we used detailed focus group sessions and developed strong community links to produce a successful community-based approach to engagement, which we hope will act as a model of testing in other communities. <h3>Disclosure of Interest</h3> None Declared
Imprint Of Early CMV Reactivation On The Reconstituting T-Lymphocyte Compartment One and Two Year After Hematopoietic Stem Cell Transplantation
Authors: Gertjan Lugthart, Monique M. van Ostaijen-Ten Dam, Cornelia M. Jol-van der Zijde, Tessa C. van Holten, Michel G.D. Kester, Mirjam H.M. Heemskerk, Robbert G.M. Bredius, Maarten J.D. van Tol, Arjan C. Lankester
Journal: Blood (2013)
Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.
Authors: Fabio R. Kerbauy, Thoralf Lange, Ted Gooley, Judith Shizuru, Jerald Radich, David G. Maloney, Edward Agura, Benedetto Bruno, Elliot Epner, Thomas Chauncey, Karl Blume, Rainer Storb, Dietger Niederwieser, Brenda M. Sandmaier
Journal: Blood (2004)